Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#41
Polina Bellman, Jesus D Gonzalez-Lugo, Moazzam Shahzad, Muhammad Kashif Amin, Muhammad Fareed Khalid, Nahid Suleman, Nausheen Ahmed, Anurag K Singh, Abdulraheem Yacoub, Da Zhang, Joseph P McGuirk, Muhammad Umair Mushtaq
Vacuoles, E1 syndrome, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a chronic inflammatory disorder that affects various organ systems. It is associated with hematologic malignancies and is generally refractory to therapies. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered for selected patients. We report a case wherein systemic and hematological manifestations completely resolved in a patient with VEXAS and associated myelodysplastic syndrome (MDS), following the administration of fludarabine and cyclophosphamide as part of the preparation for allo-HSCT...
2024: Frontiers in Oncology
#42
JOURNAL ARTICLE
Zhipeng Li, Jing Wang, Lei Deng, Ximin Liu, Fanjun Kong, Yuerong Zhao, Yixi Hou, Fang Zhou
INTRODUCTION: Chimerism is closely correlated with disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, chimerism rate is dynamic changes, and the sensitivity of different chimerism requires further research. METHODS: To investigate the predictive value of distinct chimerism for relapse, we measured bone marrow (BM), peripheral blood (PB), and T-cell (isolated from BM) chimerism in 178 patients after allo-HSCT. RESULTS: Receiver operating characteristic (ROC) curve showed that T-cell chimerism was more suitable to predict relapse after allo-HSCT compared with PB and BM chimerism...
2024: Frontiers in Immunology
#43
(no author information available yet)
Retraction: Feng, C-J. , Zhao, P. , Fu, H-X. , Yan, C-H. , Wang, C-C. , Zhu, X-L. , He, Y. , Wang, F-R. , Zhang, Y-Y. , Mo, X-D. , Kong, Y. , Han, W. , Wang, J-Z. , Wang, Y. , Chen, H. , Chen, Y-H. , Zhao, X-Y. , Chang, Y-J. , Xu, L-P. , Liu, K-Y. , Huang, X-J. , Zhang, X-H. (2023) A predictive model of herpes zoster after allogeneic hematopoietic stem cell transplantation: VZV reactivation following antiviral prophylaxis discontinuation. American Journal of Hematology. https://doi.org/10.1002/ajh.27090. The above article, published online on 29 September 2023 in Wiley Online Library (wileyonlinelibrary...
April 26, 2024: American Journal of Hematology
#44
JOURNAL ARTICLE
Wenxuan Huo, Lu Gao, Kaidi Song, Jiayu Huang, Na Wang, Leqing Cao, Yang Liu, Fengrong Wang, Chuan Li, Xiaoyu Zhu, Xiaojin Wu, Yang Cao, Xiaodong Mo, Xiaoxia Hu
In this multicentre, real-world study, we aimed to identify the clinical outcomes and safety of allogeneic haematopoietic stem cell transplantation (allo-HSCT) in T-lymphoblastic lymphoma (T-LBL). A total of 130 Ann Arbor stage III or IV T-LBL patients (>16 years) treated with allo-HSCT across five transplant centres were enrolled. The 2-year cumulative incidence of disease progression, the probabilities of progression-free survival (PFS), overall survival (OS) and non-relapse mortality (NRM) after allo-HSCT were 21...
April 25, 2024: British Journal of Haematology
#45
RANDOMIZED CONTROLLED TRIAL
Yu Wang, Qi-Fa Liu, De-Pei Wu, Zheng-Li Xu, Ting-Ting Han, Yu-Qian Sun, Fen Huang, Zhi-Ping Fan, Na Xu, Feng Chen, Ye Zhao, Yuan Kong, Xiao-Dong Mo, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
BACKGROUND: There is an urgent unmet need for effective initial treatment for acute graft-versus-host disease (aGVHD) adding to the standard first-line therapy with corticosteroids after allogeneic haematopoietic stem cell transplantation (allo-HSCT). METHODS: We performed a multicentre, open-label, randomized, phase 3 study. Eligible patients (aged 15 years or older, had received allo-HSCT for a haematological malignancy, developed aGVHD, and received no previous therapies for aGVHD) were randomly assigned (1:1) to receive either 5 mg/m2 MTX on Days 1, 3, or 8 and then combined with corticosteroids or corticosteroids alone weekly...
April 25, 2024: BMC Medicine
#46
JOURNAL ARTICLE
Rashin Mohseni, Pouya Mahdavi Sharif, Abbas Khosravi, Ahmad Reza Taheri, Maryam Behfar, Morteza Zarrabi, Leila Jafari, Fahimeh Jafari, Zeynab Nikfetrat, Parisa Naji, Amir Ali Hamidieh
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative strategy against a variety of malignant and nonmalignant disorders. However, acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) commonly complicate this approach, culminating in substantial morbidities and mortalities. The integumentary system is the preponderant organ involved in cGVHD, and its response to existing treatments, including well-versed immunosuppressants and novel targeted therapies, is not desirable...
April 23, 2024: Transplantation and cellular therapy
#47
JOURNAL ARTICLE
Julien De Greef, Dina Averbuch, Laura Tondeur, Amélie Duréault, Tsila Zuckerman, Xavier Roussel, Christine Robin, Alienor Xhaard, Simona Pagliuca, Yves Beguin, Carmen Botella-Garcia, Nina Khanna, Amandine Le Bourgeois, Jens Van Praet, Aloysius Ho, Nicolaus Kröger, Sophie Ducastelle Leprêtre, Damien Roos-Weil, Mahmoud Aljurf, Nicole Blijlevens, Igor Wolfgang Blau, Kristina Carlson, Matthew Collin, Arnold Ganser, Alban Villate, Johannes Lakner, Sonja Martin, Arnon Nagler, Ron Ram, Anna Torrent, Maria Stamouli, Malgorzata Mikulska, Lidia Gil, Lotus Wendel, Gloria Tridello, Nina Knelange, Rafael de la Camara, Olivier Lortholary, Arnaud Fontanet, Jan Styczynski, Johan Maertens, Julien Coussement, David Lebeaux
OBJECTIVES: Nocardiosis is a rare but life-threatening infection after hematopoietic cell transplantation (HCT). We aimed at identifying risk factors for nocardiosis after allogeneic HCT and clarifying the effect of trimethoprim-sulfamethoxazole prophylaxis on its occurrence. METHODS: We performed a retrospective multicenter case-control study of patients diagnosed with nocardiosis after allogeneic HCT between January 2000 and December 2018. For each case, two controls were matched by center, transplant date, and age group...
April 23, 2024: Journal of Infection
#48
JOURNAL ARTICLE
Alison Moe, Aditya Rayasam, Garrett Sauber, Ravi K Shah, Ashley Doherty, Cheng-Yin Yuan, Aniko Szabo, Bob M Moore Ii, Marco Colonna, Weiguo Cui, Julian Romero, Anthony E Zamora, Cecilia J Hillard, William R Drobyski
Neuroinflammation is a recognized complication of immunotherapeutic approaches such as immune checkpoint inhibitor treatment, chimeric antigen receptor therapy, and graft versus host disease (GVHD) occurring after allogeneic hematopoietic stem cell transplantation. While T cells and inflammatory cytokines play a role in this process, the precise interplay between the adaptive and innate arms of the immune system that propagates inflammation in the central nervous system remains incompletely understood. Using a murine model of GVHD, we demonstrate that type 2 cannabinoid receptor (CB2R) signaling plays a critical role in the pathophysiology of neuroinflammation...
April 25, 2024: Journal of Clinical Investigation
#49
JOURNAL ARTICLE
S J Jessop, N Fuentos-Bolanos, C Mayoh, M E M Dolman, G Tax, M Wong-Erasmus, P Ajuyah, V Tyrell, G M Marshall, D S Ziegler, L M S Lau
BACKGROUND: Despite advances in therapeutics for adverse-risk acute myeloid leukaemia (AML), overall survival remains poor, especially in refractory disease. Comprehensive tumour profiling and pre-clinical drug testing can identify effective personalised therapies. CASE: We describe a case of ETV6-MECOM fusion-positive refractory AML, where molecular analysis and in vitro high throughput drug screening identified a tolerable, novel targeted therapy and provided rationale for avoiding what could have been a toxic treatment regimen...
April 2024: Cancer reports
#50
JOURNAL ARTICLE
Kumiyo Tazoe, Naonori Harada, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
Myelodysplastic syndrome (MDS) is well known to be complicated by systemic inflammatory autoimmune disease (SIADs). However, it remains unclear how the prognosis after allogenic hematopoietic stem cell transplantation (allo-HSCT) in patients with MDS is impacted by SIADs that occur before allo-HSCT. Therefore, we hypothesized that SIADs before allo-HSCT may be a risk factor for negative outcomes after allo-HSCT in patients with MDS. We conducted a single-center, retrospective, observational study of sixty-nine patients with MDS or chronic myelomonocytic leukemia who underwent their first allo-HCT...
April 25, 2024: Annals of Hematology
#51
REVIEW
Shu-Hui Xu, Yan Man, Jin-Lian Zhao, Ya-Jie Wang
Chronic graft-versus-host disease (cGVHD) is one of a major complication that affecting the long-term survival and living quality of patients after allogeneic hematopoietic stem cell transplantation, with the incidence of 30%-70%. Unlike acute GVHD, cGVHD involves a large number of immune cells and cytokines in addition to T cell, which is activated abnormally by the donor, and cytokine storms, which characterized by infiltration of donor lymphocytes and damage to host target organ. Recent studies have further made progress in targeting related immune cells and cytokines...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
#52
JOURNAL ARTICLE
Zhi-Wei Wang, Qiong Liu, Hai-Ying Sun
OBJECTIVE: To explore the clinical characteristics and risk factors of cytomegalovirus(CMV) and Epstein-Barr virus(EBV) co-reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its influence on prognosis. METHODS: The clinical data of 222 patients who received allo-HSCT from January 2015 to December 2020 were collected, and the patients were divided into groups according to the occurrence of CMV and EBV infection. Kaplan-Meier method was used for survival analysis, and Cox proportional hazard regression model was used to analyze the risk factors of co-reactivation of CMV and EBV...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
#53
JOURNAL ARTICLE
Ru-Yu Liu, Chang-Lin Yu, Jian-Hui Qiao, Bo Cai, Qi-Yun Sun, Yi Wang, Tie-Qiang Liu, Shan Jiang, Tian-Yao Zhang, Hui-Sheng Ai, Mei Guo, Kai-Xun Hu
OBJECTIVE: To explore the role of NK cells in allogeneic hematopoietic stem cell micro-transplantation(MST) in the treatment of patients with acute myeloid leukemia(AML). METHODS: Data from 93 AML patients treated with MST at our center from 2013-2018 were retrospectively analyzed. The induction regimen was anthracycline and cytarabine combined with peripheral blood stem cells transplantation mobilization by granulocyte colony stimulating factor (GPBSC), followed by 2-4 courses of intensive treatment with medium to high doses of cytarabine combined with GPBSC after achieving complete remission (CR)...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
#54
JOURNAL ARTICLE
Ruo-Qi Shan, Sai Huang, Zhen-Yang Gu, Nan Wang, Dai-Hong Liu, Li-Ping Dou
OBJECTIVE: To investigate the clinical characteristics, coexisting gene mutations and prognosis of acute myeloid leukemia (AML) patients with GATA2 gene mutation. METHODS: The clinical data of 370 newly diagnosed AML patients treated in our hospital from January 2008 to January 2021 was analyzed retrospectively, the next-generation sequencing technology was used to detect the mutated genes in those patients. The clinical characteristics of AML patients with GATA2 mutations, the co-mutated genes of GATA2 mutations, and the effect of GATA2 mutation on prognosis were analyzed...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
#55
JOURNAL ARTICLE
Ruonan Zhang, Yiying Xiong, Linyi Zhang, Lin Liu
PURPOSE: To investigate the clinical characteristics, etiology, and risk factors of bacterial bloodstream infection (BSI) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. This study also aimed to provide a clinical basis for early identification of high-risk patients and optimization of empirical antimicrobial treatment. PATIENTS AND METHODS: This is a retrospective study of clinical data during agranulocytosis from 331 patients with hematological malignancies who underwent allo-HSCT at our institute between January 2016 and December 2022...
2024: Infection and Drug Resistance
#56
JOURNAL ARTICLE
Ceyhun Bozkurt, Volkan Hazar, Barış Malbora, Alphan Küpesiz, Utku Aygüneş, Tunç Fışgın, Musa Karakükçü, Barış Kuşkonmaz, Suar Çakı Kılıç, Derya Bayırlı, Özlem Arman Bilir, Koray Yalçın, Salih Gözmen, Vedat Uygun, Murat Elli, Hakan Sarbay, Funda Tayfun Küpesiz, Hatice İlgen Şaşmaz, Başak Adaklı Aksoy, Ebru Yılmaz, Fatma Visal Okur, Funda Tekkeşin, Fatma Demir Yenigürbüz, Gülcihan Özek, Abdullah Avni Atay, İkbal Ok Bozkaya, Suna Çelen, Seda Öztürkmen, Adalet Meral Güneş, Orhan Gürsel, Elif Güler, Alper Özcan, Duygu Uçkan Çetinkaya, Selime Aydoğdu, Namık Yaşar Özbek, Gülsün Karasu, Gülay Sezgin, Ömer Doğru, Davut Albayrak, Gülyüz Öztürk, Serap Aksoylar, Hayriye Daloğlu, Işık Odaman Al, Melike Sezgin Evim, Sinan Akbayram, Yurday Öncül, Emine Zengin, Canan Albayrak, Çetin Timur, Yeter Düzenli Kar, Hasan Fatih Çakmaklı, Özlem Tüfekçi, Ersin Töret, Bülent Antmen
BACKGROUND: Data on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited. OBJECTIVES: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID-19 infection. METHOD: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID-19 between March 2020 and August 2022...
May 2024: Pediatric Transplantation
#57
JOURNAL ARTICLE
Gökcan Öztürk, Deniz Bayrakoğlu, Şule Haskoloğlu, Kübra Baskın, Nazlı Deveci, Elif İnce, Talia İleri, Hasan Çakmaklı, Mehmet Ertem, Aydan İkincioğulları, Figen Doğu
BACKGROUND/AIM: There are several complications of hematopoietic stem cell transplantation. Without any doubt, most important of these is aGvHD that increases transplant-related mortality. The aim of this study is to investigate whether ST-2 and Reg3α levels measured at an early stage in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation can be individual biomarkers identifying future GvHD and predicting treatment response. MATERIALS AND METHODS: From January 2019 to January 2021, 27 patients undergoing hematopoietic stem cell transplantation for primary immunodeficiency or hematopoietic diseases formed the study group...
April 17, 2024: Hematology, Transfusion and Cell Therapy
#58
JOURNAL ARTICLE
Ryu Matsumoto, Yin Enzhi, Kazuyoshi Takeda, Kodai Morimoto, Kyoko Yogo, Masaki Harada, Koji Tokushige, Yui Maehara, Saori Hirota, Yuko Kojima, Mamoru Ito, Nagako Sougawa, Shigeru Miyagawa, Yoshiki Sawa, Ko Okumura, Koichiro Uchida
BACKGROUND: Transplantation of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) has emerged as a promising therapy to treat end-stage heart failure. However, immunogenicity of hiPS-CMs in transplanted patients has not been fully elucidated. Thus, in vivo models are required to estimate immune responses against hiPS-CMs in transplant recipients. METHODS: We transferred human peripheral blood mononuclear cells (hPBMCs) into NOD/Shi-scid IL2rgnull (NOG) MHC class I/II double knockout (NOG-ΔMHC) mice, which were reported to accept hPBMCs without xenogeneic-graft-versus-host disease (xeno-GVHD)...
April 22, 2024: Journal of Heart and Lung Transplantation
#59
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Tadao Ishida
INTRODUCTION: Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association between elotuzumab and CMVRA. Therefore, we assessed the incidence of CMVRA in patients with MM who received elotuzumab therapy. METHODS: The medical records of 85 patients who underwent elotuzumab therapy were included in the retrospective analysis for CMV positivity. RESULTS: Thirty patients were tested for CMV antigenemia during elotuzumab therapy, and 16 were positive for CMV antigenemia; the cumulative incidence rate of CMVRA six months after elotuzumab initiation was 18...
April 24, 2024: Acta Haematologica
#60
EDITORIAL
Didier Blaise
New England Journal of Medicine, Volume 390, Issue 16, Page 1526-1527, April 25, 2024.
April 25, 2024: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
